Fluocinonide ointment псориаз
Rated 5/5 based on 150 student reviews

Fluocinonide ointment псориаз. Витамин д лечение псориаза. 2019-01-19 06:10

Fluocinonide ointment эффективно борется с аллергическими высыпаниями и грибковыми образованиями на коже. Мазь «Флуоцинонид Оинтмент» на основе кортикостероида применяется при таких кожных заболеваниях как: Производитель КНР Нанести локально на поврежденные участки 2-3 р в день, но не более 5 г в неделю! При длительном и непрерывном использовании возможны побочные эффекты в виде кожной атрофии и дилатации капилярных кровеносных сосудов. Чтобы исключить подобные проявления рекомендуется делать перерывы по 1-2 недели или более, не используя данную мазь. The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. A significantly greater amount of fluocinonide is absorbed from the solution than from the cream or gel formulations. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses. (See DOSAGE AND ADMINISTRATION.) Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile. Fluocinonide Cream USP, 0.05%, Fluocinonide Cream USP, 0.05% (Emulsified Base), Fluocinonide Gel USP, 0.05% and Fluocinonide Ointment USP, 0.05% and Flucinonide Topical Solution USP are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.

Экзема, псориаз, дерматиты – это заболевания кожи, которые способны сильно подпортить жизнь человеку, тяжело поддаются лечению и подвержены рецидивам. Может быть, это происходит из-за того, что причины возникновения этих заболеваний официальной медициной до конца не изучены. Псориаз – это заболевание кожи, от которого страдает около 4% населения Земли, которое поражает людей всех возрастов – от младенцев до людей пожилого возраста. Псориаз поражает кожные покровы, чаще всего на локтях, суставах и коже головы, а также ногти. Экзема чаще всего поражает открытые участки кожи (лицо, руки, стопы), является хроническим заболеванием, которое протекает с периодами ремиссии и обострения. Считается, что в основе этих заболевания псориазом и экземой лежит совокупность причин: иммунологические сдвиги, нарушение обмена веществ, эндокринные и неврологические расстройства. Дерматит – это острое воспалительное поражение кожи, большей частью развивающееся в ответ на действие какого-либо аллергена. Чаще всего встречаются аллергический, атопический и себорейный дерматит. Также дерматиты чаще встречаются у детей, в следствие возрастными трудностями в работе иммунной системы. Если Вы страдаете каким-либо из этих заболеваний, попробуйте лечение дерматитов, псориаза или экземы тайскими традиционными средствами. Они отличаются от всего, что вы можете приобрести в наших местных аптеках, в первую очередь, своим чудотворным составом. Использование экстрактов тайских растений, которые сочетают эффективность и безопасность, древнейшая рецептура и принцип «не навреди» делают препараты из Таиланда лучшим выбором для лечения псориаза, экземы и дерматитов. Plaque psoriasis typically appears as raised areas of inflamed skin covered with silvery-white scaly skin. These areas are called plaques and are most commonly found on the elbows, knees, scalp, and back. Psoriatic erythroderma (erythrodermic psoriasis) involves widespread inflammation and exfoliation of the skin over most of the body surface. It may be accompanied by severe itching, swelling, and pain. It is often the result of an exacerbation of unstable plaque psoriasis, particularly following the abrupt withdrawal of systemic glucocorticoids. Inverse psoriasis (also known as flexural psoriasis) appears as smooth, inflamed patches of skin. The patches frequently affect skin folds, particularly around the genitals (between the thigh and groin), the armpits, in the skin folds of an overweight abdomen (known as panniculus), between the buttocks in the intergluteal cleft, and under the breasts in the inframammary fold. Heat, trauma, and infection are thought to play a role in the development of this atypical form of psoriasis. Guttate psoriasis is characterized by numerous small, scaly, red or pink, droplet-like lesions (papules). These numerous spots of psoriasis appear over large areas of the body, primarily the trunk, but also the limbs and scalp. Guttate psoriasis is often triggered by a streptococcal infection, typically streptococcal pharyngitis. in contrast to lichen planus, another common papulosquamous disorder that commonly involves both the skin and mouth. When psoriasis involves the oral mucosa (the lining of the mouth), it may be asymptomatic, Fissured tongue is the most common finding in those with oral psoriasis and has been reported to occur in 6.5–20% of people with psoriasis affecting the skin. The microscopic appearance of oral mucosa affected by geographic tongue (migratory stomatitis) is very similar to the appearance of psoriasis. Seborrheic-like psoriasis is a common form of psoriasis with clinical aspects of psoriasis and seborrheic dermatitis, and it may be difficult to distinguish from the latter. This form of psoriasis typically manifests as red plaques with greasy scales in areas of higher sebum production such as the scalp, forehead, skin folds next to the nose, skin surrounding the mouth, skin on the chest above the sternum, and in skin folds. It typically involves painful inflammation of the joints and surrounding connective tissue and can occur in any joint, but most commonly affects the joints of the fingers and toes. This can result in a sausage-shaped swelling of the fingers and toes known as dactylitis. Psoriasis can affect the nails and produces a variety of changes in the appearance of finger and toe nails. Nail psoriasis occurs in 40–45% of people with psoriasis affecting the skin and has a lifetime incidence of 80–90% in those with psoriatic arthritis. These changes include pitting of the nails (pinhead-sized depressions in the nail is seen in 70% with nail psoriasis), whitening of the nail, small areas of bleeding from capillaries under the nail, yellow-reddish discoloration of the nails known as the oil drop or salmon spot, thickening of the skin under the nail (subungual hyperkeratosis), loosening and separation of the nail (onycholysis), and crumbling of the nail. In addition to the appearance and distribution of the rash, specific medical signs may be used by medical practitioners to assist with diagnosis. These may include Auspitz's sign (pinpoint bleeding when scale is removed), Koebner phenomenon (psoriatic skin lesions induced by trauma to the skin), Around one-third of people with psoriasis report a family history of the disease, and researchers have identified genetic loci associated with the condition. Identical twin studies suggest a 70% chance of a twin developing psoriasis if the other twin has the disorder. These findings suggest both a genetic susceptibility and an environmental response in developing psoriasis. Psoriasis has a strong hereditary component, and many genes are associated with it, but it is unclear how those genes work together. Most of the identified genes relate to the immune system, particularly the major histocompatibility complex (MHC) and T cells. Genetic studies are valuable due to their ability to identify molecular mechanisms and pathways for further study and potential drug targets. Classic genome-wide linkage analysis has identified nine loci on different chromosomes associated with psoriasis. They are called psoriasis susceptibility 1 through 9 (PSORS1 through PSORS9). Within those loci are genes on pathways that lead to inflammation. Certain variations (mutations) of those genes are commonly found in psoriasis. Genome-wide association scans have identified other genes that are altered to characteristic variants in psoriasis. Some of these genes express inflammatory signal proteins, which affect cells in the immune system that are also involved in psoriasis. Some of these genes are also involved in other autoimmune diseases. It controls genes that affect the immune system or encode skin proteins that are overabundant with psoriasis. PSORS1 is located on chromosome 6 in the major histocompatibility complex (MHC), which controls important immune functions. Three genes in the PSORS1 locus have a strong association with psoriasis vulgaris: HLA-C variant HLA-Cw6, which encodes a MHC class I protein; CCHCR1, variant WWC, which encodes a coiled protein that is overexpressed in psoriatic epidermis; and CDSN, variant allele 5, which encodes corneodesmosin, a protein which is expressed in the granular and cornified layers of the epidermis and upregulated in psoriasis. Two major immune system genes under investigation are interleukin-12 subunit beta (IL12B) on chromosome 5q, which expresses interleukin-12B; and IL23R on chromosome 1p, which expresses the interleukin-23 receptor, and is involved in T cell differentiation. Interleukin-23 receptor and IL12B have both been strongly linked with psoriasis. Recently, the first gene directly linked to psoriasis has been identified. A rare mutation in the gene encoding for the CARD14 protein plus an environmental trigger was enough to cause plaque psoriasis (the most common form of psoriasis). It is hypothesized that the diminished CD4 -T cell presence causes an overactivation of CD8 -T cells, which are responsible for the exacerbation of psoriasis in HIV-positive people. Psoriasis in those with HIV/AIDS is often severe and may be untreatable with conventional therapy. These changes are believed to stem from the premature maturation of keratinocytes induced by an inflammatory cascade in the dermis involving dendritic cells, macrophages, and T cells (three subtypes of white blood cells). These immune cells move from the dermis to the epidermis and secrete inflammatory chemical signals (cytokines) such as interleukin-36γ, tumor necrosis factor-α, interleukin-1β, interleukin-6, and interleukin-22. In response to these chemical messages from dendritic cells and T cells, keratinocytes also secrete cytokines such as interleukin-1, interleukin-6, and tumor necrosis factor-α, which signal downstream inflammatory cells to arrive and stimulate additional inflammation. and induce the proliferation of T cells and type 1 helper T cells (Th1). Targeted immunotherapy as well as psoralen and ultraviolet A (PUVA) therapy can reduce the number of dendritic cells and favors a Th2 cell cytokine secretion pattern over a Th1/Th17 cell cytokine profile. A diagnosis of psoriasis is usually based on the appearance of the skin. Skin characteristics typical for psoriasis are scaly, erythematous plaques, papules, or patches of skin that may be painful and itch. The differential diagnosis of psoriasis includes dermatological conditions similar in appearance such as discoid eczema, seborrhoeic eczema, pityriasis rosea (may be confused with guttate psoriasis), nail fungus (may be confused with nail psoriasis) or cutaneous T cell lymphoma (50% of individuals with this cancer are initially misdiagnosed with psoriasis). If the clinical diagnosis is uncertain, a skin biopsy or scraping may be performed to rule out other disorders and to confirm the diagnosis. Skin from a biopsy will show clubbed epidermal projections that interdigitate with dermis on microscopy. Epidermal thickening is another characteristic histologic finding of psoriasis lesions. The stratum granulosum layer of the epidermis is often missing or significantly decreased in psoriatic lesions; the skin cells from the most superficial layer of skin are also abnormal as they never fully mature. Unlike their mature counterparts, these superficial cells keep their nucleus. Inflammatory infiltrates can typically be visualized on microscopy when examining skin tissue or joint tissue affected by psoriasis. Epidermal skin tissue affected by psoriatic inflammation often has many CD8 T cells while a predominance of CD4 T cells makes up the inflammatory infiltrates of the dermal layer of skin and the joints. Another classification scheme considers genetic and demographic factors. Type 1 has a positive family history, starts before the age of 40, and is associated with the human leukocyte antigen, HLA-Cw6. Conversely, type 2 does not show a family history, presents after age 40, and is not associated with HLA-Cw6. The classification of psoriasis as an autoimmune disease has sparked considerable debate. Researchers have proposed differing descriptions of psoriasis and psoriatic arthritis; some authors have classified them as autoimmune diseases There is no consensus about how to classify the severity of psoriasis. Mild psoriasis has been defined as a percentage of body surface area (BSA)≤10, a Psoriasis Area Severity Index (PASI) score ≤10, and a dermatology life quality index (DLQI) score ≤10. The DLQI is a 10 question tool used to measure the impact of several dermatologic diseases on daily functioning. The DLQI score ranges from 0 (minimal impairment) to 30 (maximal impairment) and is calculated with each answer being assigned 0–3 points with higher scores indicating greater social or occupational impairment. The psoriasis area severity index (PASI) is the most widely used measurement tool for psoriasis. PASI assesses the severity of lesions and the area affected and combines these two factors into a single score from 0 (no disease) to 72 (maximal disease). Greater benefit has been observed with very potent corticosteroids when compared to potent corticosteroids. Vitamin D analogues such as paricalcitol were found to be significantly superior to placebo. Combination therapy with vitamin D and a corticosteroid was superior to either treatment alone and vitamin D was found to be superior to coal tar for chronic plaque psoriasis. Moisturizers and emollients such as mineral oil, petroleum jelly, calcipotriol, and decubal (an oil-in-water emollient) were found to increase the clearance of psoriatic plaques. Emollients have been shown to be even more effective at clearing psoriatic plaques when combined with phototherapy. However, certain emollients have no impact on psoriasis plaque clearance or may even decrease the clearance achieved with phototherapy. The emollient salicylic acid is structurally similar to para-aminobenzoic acid (PABA), commonly found in sunscreen, and is known to interfere with phototherapy in psoriasis. Coconut oil, when used as an emollient in psoriasis, has been found to decrease plaque clearance with phototherapy. Medicated creams and ointments applied directly to psoriatic plaques can help reduce inflammation, remove built-up scale, reduce skin turnover, and clear affected skin of plaques. Ointment and creams containing coal tar, dithranol, corticosteroids (i.e. desoximetasone), fluocinonide, vitamin D Another topical therapy used to treat psoriasis is a form of balneotherapy, which involves daily baths in the Dead Sea. This is usually done for four weeks with the benefit attributed to sun exposure and specifically UVB light. This is cost-effective and it has been propagated as an effective way to treat psoriasis without medication. Data are inconclusive with respect to nonmelanoma skin cancer risk, but support the idea that the therapy is associated with an increased risk of benign forms of sun-induced skin damage such as, but not limited to, actinic elastosis or liver spots. The exposure time should be controlled to avoid over exposure and burning of the skin. The UVB lamps should have a timer that will turn off the lamp when the time ends. The amount of light used is determined by a person's skin type. One of the problems with clinical phototherapy is the difficulty many patients have gaining access to a facility. Indoor tanning resources are almost ubiquitous today and could be considered as a means for patients to get UV exposure when dermatologist provided phototherapy is not available. Indoor tanning is already used by many people as a treatment for psoriasis; one indoor facility reported that 50% of its clients were using the center for psoriasis treatment; another reported 36% were doing the same thing. However, a concern with the use of commercial tanning is that tanning beds that primarily emit UVA might not effectively treat psoriasis. One study found that plaque psoriasis is responsive to erythemogenic doses of either UVA or UVB, as exposure to either can cause dissipation of psoriatic plaques. It does require more energy to reach erythemogenic dosing with UVA. UV light therapies all have risks; tanning beds are no exception, particularly in the link between UV light and the increased chance of skin cancer. There are increased risks of melanoma, squamous cell and basal cell carcinomas; younger psoriasis patients, particularly those under age 35, are at increased risk from melanoma from UV light treatment. The World Health Organization (WHO) listed tanning beds as carcinogens. A review of studies recommends that people who are susceptible to skin cancers exercise caution when using UV light therapy as a treatment. A major mechanism of NBUVB is the induction of DNA damage in the form of pyrimidine dimers. This type of phototherapy is useful in the treatment of psoriasis because the formation of these dimers interferes with the cell cycle and stops it. The interruption of the cell cycle induced by NBUVB opposes the characteristic rapid division of skin cells seen in psoriasis. The activity of many types of immune cells found in the skin is also effectively suppressed by NBUVB phototherapy treatments. The most common short-term side effect of this form of phototherapy is redness of the skin; less common side effects of NBUVB phototherapy are itching and blistering of the treated skin, irritation of the eyes in the form of conjunctival inflammation or inflammation of the cornea, or cold sores due to reactivation of the herpes simplex virus in the skin surrounding the lips. Eye protection is usually given during phototherapy treatments. Psoralen and ultraviolet A phototherapy (PUVA) combines the oral or topical administration of psoralen with exposure to ultraviolet A (UVA) light. The mechanism of action of PUVA is unknown, but probably involves activation of psoralen by UVA light, which inhibits the abnormally rapid production of the cells in psoriatic skin. There are multiple mechanisms of action associated with PUVA, including effects on the skin's immune system. PUVA is associated with nausea, headache, fatigue, burning, and itching. Long-term treatment is associated with squamous cell carcinoma (but not with melanoma). Pregnancy must be avoided for most of these treatments. The majority of people experience a recurrence of psoriasis after systemic treatment is discontinued. Non-biologic systemic treatments frequently used for psoriasis include methotrexate, ciclosporin, hydroxycarbamide, fumarates such as dimethyl fumarate, and retinoids. Biologics are manufactured proteins that interrupt the immune process involved in psoriasis. Unlike generalised immunosuppressive drug therapies such as methotrexate, biologics target specific aspects of the immune system contributing to psoriasis. The safety of biologics during pregnancy has not been assessed. European guidelines recommend avoiding biologics if a pregnancy is planned; anti-TNF therapies such as infliximab are not recommended for use in chronic carriers of the hepatitis B virus or individuals infected with HIV. Several monoclonal antibodies target cytokines, the molecules that cells use to send inflammatory signals to each other. TNF-α is one of the main executor inflammatory cytokines. Four monoclonal antibodies (MAbs) (infliximab, adalimumab, golimumab, and certolizumab pegol) and one recombinant TNF-α decoy receptor, etanercept, have been developed to inhibit TNF-α signaling. Additional monoclonal antibodies, such as ixekizumab, It also blocks the adhesion molecules on the endothelial cells that line blood vessels, which attract T cells. Efalizumab was voluntarily withdrawn from the European market in February 2009 and from the US market in June 2009 by the manufacturer due to the medication's association with cases of progressive multifocal leukoencephalopathy. Individuals with psoriasis may develop neutralizing antibodies against monoclonal antibodies. Neutralization occurs when an antidrug antibody prevents a monoclonal antibody such as infliximab from binding antigen in a laboratory test. Specifically, neutralization occurs when the antidrug antibody binds to infliximab's antigen binding site instead of TNF-α. When infliximab no longer binds tumor necrosis factor alpha, it no longer decreases inflammation, and psoriasis may worsen. Neutralizing antibodies have not been reported against etanercept, a biologic drug that is a fusion protein composed of two TNF-α receptors. The lack of neutralizing antibodies against etanercept is probably secondary to the innate presence of the TNF-α receptor, and the development of immune tolerance. Uncontrolled studies have suggested that individuals with psoriasis or psoriatic arthritis may benefit from a diet supplemented with fish oil rich in eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Diet recommendations include consumption of cold water fish (preferably wild fish, not farmed) such as salmon, herring, and mackerel; extra virgin olive oil; legumes; vegetables; fruits; and whole grains; and avoid consumption of alcohol, red meat, and dairy products. The effect of consumption of caffeine (including coffee, black tea, mate, and dark chocolate) remains to be determined. Depending on the severity and location of outbreaks, individuals may experience significant physical discomfort and some disability. Itching and pain can interfere with basic functions, such as self-care and sleep. Individuals with psoriasis may feel self-conscious about their appearance and have a poor self-image that stems from fear of public rejection and psychosexual concerns. Psoriasis has been associated with low self-esteem and depression is more common among those with the condition. Many tools exist to measure the quality of life of patients with psoriasis and other dermatological disorders. Nearly half of individuals with psoriasis over the age of 65 have at least three comorbidities (concurrent conditions), and two-thirds have at least two comorbidities. Clinical research has indicated individuals often experience a diminished quality of life. Individuals with psoriasis or psoriatic arthritis have a slightly higher risk of heart disease and heart attacks when compared to the general population. Cardiovascular disease risk appeared to be correlated with the severity of psoriasis and its duration. There is no strong evidence to suggest that psoriasis is associated with an increased risk of death from cardiovascular events. Methotrexate may provide a degree of protection for the heart. The odds of having hypertension are 1.58 times higher in people with psoriasis than those without the condition; these odds are even higher with severe cases of psoriasis. A similar association was noted in people who have psoriatic arthritis—the odds of having hypertension were found to be 2.07 times greater when compared to odds of the general population. The link between psoriasis and hypertension is not currently understood. Mechanisms hypothesized to be involved in this relationship include the following: dysregulation of the renin-angiotensin system, elevated levels of endothelin 1 in the blood, and increased oxidative stress. Treating high levels of cholesterol with statins has been associated with decreased psoriasis severity, as measured by PASI score, and has also been associated with improvements in other cardiovascular disease risk factors such as markers of inflammation. These cardioprotective effects are attributed to ability of statins to improve blood lipid profile and because of their anti-inflammatory effects. Statin use in those with psoriasis and hyperlipidemia was associated with decreased levels of high-sensitivity C-reactive protein and TNFα as well as decreased activity of the immune protein LFA-1. People with psoriasis have a 52% increased risk cancers of the lung and bronchus, a 205% increase in the risk of developing cancers of the upper gastrointestinal tract, a 31% increase in the risk of developing cancers of the urinary tract, a 90% increase in the risk of developing liver cancer, and a 46% increase in the risk of developing pancreatic cancer. The risk for development of non-melanoma skin cancers is also increased. Psoriasis increases the risk of developing squamous cell carcinoma of the skin by 431% and increases the risk of basal cell carcinoma by 100%. It can occur at any age, although it most commonly appears for the first time between the ages of 15 and 25 years. Approximately one third of people with psoriasis report being diagnosed before age 20. Scholars believe psoriasis to have been included among the various skin conditions called tzaraath (translated as leprosy) in the Hebrew Bible, a condition imposed as a punishment for slander. The patient was deemed "impure" (see tumah and taharah) during their afflicted phase and is ultimately treated by the kohen. However, it is more likely that this confusion arose from the use of the same Greek term for both conditions. The Greeks used the term lepra (λεπρα) for scaly skin conditions. They used the term psora to describe itchy skin conditions. It became known as Willan's lepra in the late 18th century when English dermatologists Robert Willan and Thomas Bateman differentiated it from other skin diseases. Leprosy, they said, is distinguished by the regular, circular form of patches, while psoriasis is always irregular. Willan identified two categories: leprosa graecorum and psora leprosa. Psoriasis is thought to have first been described in Ancient Rome by Cornelius Celsus. The disease was first classified by English physician Thomas Willan. The British dermatologist Thomas Bateman described a possible link between psoriasis and arthritic symptoms in 1813. The history of psoriasis is littered with treatments of dubious effectiveness and high toxicity. In the 18th and 19th centuries, Fowler's solution, which contains a poisonous and carcinogenic arsenic compound, was used by dermatologists as a treatment for psoriasis. from psora, "itch" and -iasis, "action, condition". The International Federation of Psoriasis Associations (IFPA) is the global umbrella organization for national and regional psoriasis patient associations and also gathers the leading experts in psoriasis and psoriatic arthritis research for scientific conferences every three years. The Psoriasis International Network, a program of the Fondation René Touraine, gathers dermatologists, rheumatologists and other caregivers involved in the management of psoriasis. Non-profit organizations the National Psoriasis Foundation in the United States, the Psoriasis Association in the United Kingdom and Psoriasis Australia offer advocacy and education about psoriasis in their respective countries. The annual cost for treating psoriasis in the US is estimated as high as .5 billion, including .2 billion in direct costs. Pharmacy costs are the main source of direct expense, with biologic therapy the most prevalent. These costs increase significantly when co-morbid conditions such as heart disease, hypertension, diabetes, lung disease and psychiatric disorders are factored in. Expenses linked to co-morbidities are estimated at an additional ,000 per patient per year. The role of insulin resistance in the pathogenesis of psoriasis is currently under investigation. Preliminary research has suggested that antioxidants such as polyphenols may have beneficial effects on the inflammation characteristic of psoriasis. Oral agents being investigated as alternatives to medications administered by injection include Janus kinase inhibitors, protein kinase C inhibitors, mitogen-activated protein kinase inhibitors, and phosphodiesterase 4 inhibitors, all of which have proven effective in various phase 2 and 3 clinical trials.

Fluocinonide ointment псориаз

Крем для лечения заболеваний кожи FLUOCINONIDE OINTMENT.

Детальное описание товара Уникальный и простой по своей структуре препарат для лечения псориаза Compound Fluocinonide Tincture обладает ярко выраженным воздействием на проблемные участки кожи. Способен за короткие сроки избавить от проблемных проявлений псориаза на коже и волосистой части головы. При поврежденном волосяном покрове лосьон наносится только в разбавленном виде с этиловым спиртом в пропорции 1:1. Результат применения лосьона «Чистое тело»: через 3-4 дня применения видимый результат: отсутствие шелушения и раздражения; через 7-10 дней применения бляшки становятся едва различимыми по цвету пятнышками и их количество сводится к минимуму. Оказывает противовоспалительное и антиалергенное воздействие. Восстанавливает поверхностный слой кожи за короткий срок. Уникальный и простой по своей структуре лосьон от псориаза обладает ярко выраженным воздействием на проблемные участки кожи. Состав: флюоцинонид, фтористая кислота, салициловая кислота, борнейская камфара, этанол и др. Способ применения: Лосьон наносится кисточкой, прилагаемой в комплекте, на поврежденные участки кожи 2 раза в сутки, желательно утром и вечером. Не допускать попадание в глаза, не подходит для лечения младенцев, для детей лосьон следует разводить в пропорциях как для головы, использовать с осторожностью во время беременности и лактации, при возникновении раздражения на коже следует немедленно прекратить использование данного препарата. нормализует микроциркуляцию крови, сужая периферические капилляры; 3. Показания к применению: псориаз; экзема; грибок; нейродерматит; нейродерматоз и др. дезинфицирует места поражений, что очень важно для профилактики вторичной инфекции при расчесывании. Оказывает противовоспалительное и антиалергенное воздействие. Восстанавливает поверхностный слой кожи за короткий срок. Лосьон от псориаза широко используется при лечении псориаза и нейродерматитов. Результаты применения лосьона от псориаза: Описание: жидкость светло коричневого или темно желтого и прозрачного цвета. Способен за короткие сроки избавить от проблемных проявлений на коже и волосистой части головы. Фармокологическое действие: фтор и уксусная кислота, содержащиеся в данном препарате, обладают противовоспалительным свойством. Может произойти воспаление на данном участке, уменьшение проходимости в капиллярных сосудах, уменьшение воспалительных процессов на ранних этапах, прилив крови, отек и увлажнение клеток, а также другие симптомы. Лосьон от псориаза обладает антиаллергенным свойством. Салициловая кислота растворяет кутикулу кожи, вместе с тем уничтожает бактерии. Показания к применению: при псориазе, нейродерматите и нейродерматозе. кисточка Адрес производителя: № 105, Донлин Road, Донлин, Шеньян, Ляонин, Китай. Fluocinonide Ointment, 0.05% is intended for topical administration. The active component is the corticosteroid fluocinonide, which is the 21-acetate ester of fluocinolone acetonide and has the chemical name pregna-1,4-diene-3,20-dione,21-(acetyloxy)-6,9-difluoro-11-hydroxy-16,17-[(1-methylethylidene)bis(oxy)]-,(6α,11β,16α)-. It has the following chemical structure: Fluocinonide Ointment contains fluocinonide 0.5 mg/g in a specially formulated ointment base consisting of glyceryl monostearate, white petrolatum, propylene carbonate, propylene glycol and white wax. It provides the occlusive and emollient effects desirable in an ointment. In this formulation, the active ingredient is totally in solution. Topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses (see DOSAGE AND ADMINISTRATION). Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile. Fluocinonide Ointment is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients. Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid. Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids. Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (see PRECAUTIONS – Pediatric Use). If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted. As with any topical corticosteroid product, prolonged use may produce atrophy of the skin and subcutaneous tissues. When used on intertriginous or flexor areas, or on the face, this may occur even with short-term use. In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled. Patients using topical corticosteroids should receive the following information and instructions: The following tests may be helpful in evaluating the HPA axis suppression: Urinary free cortisol test ACTH stimulation test Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids. Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results. Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman. Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced hypothalmic-pituitary-adrenal (HPA) axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio. HPA axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children. The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS). Fluocinonide Ointment is generally applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of the occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted. Fluocinonide Ointment, 0.05% is supplied in 15 g Tube – NDC 43199-029-15 30 g Tube – NDC 43199-029-30 60 g Tube – NDC 43199-029-60 Store at room temperature.

Я – доктор Мясников, и мы начинаем нашу передачу «О самом главном», в которой говорим о нашем здоровье. Как не заболеть, а если все же заболел, что делать? Псориаз или чешуйчатый лишай — это хроническое неинфекционное заболевание, разновидность дерматоза, поражающего в основном кожу. Что предпринять, чтобы как можно дольше сохранить свое здоровье? На сегодня ученые предполагают аутоиммунную природу псориаза. Сливаясь друг с другом, они и образуют псориазные бляшки. Давайте узнаем всю правду о псориазе, давайте разберемся, кому он может угрожать. Поможет нам доктор Ирина Гостева, врач-дерматолог, кандидат медицинских наук. Александр Мясников: "Ирина, расскажите, пожалуйста, от чего возникает псориаз и почему? Есть даже премия, учрежденная миллиардерами Ротшильдами в конце XIX века. Она достанется тому человеку или той организации, которые, наконец, узнают причину возникновения псориаза." Александр Мясников: "Вы уже назвали одну из причин - генетическая предрасположенность. То есть, мы можем сказать так: причины возникновения заболевания неизвестны, но известны категории риска - люди, больше всего подверженные псориазу. Есть множество теорий, которые все равно отталкиваются от нарушения иммунитета в организме человека. Давайте их рассмотрим." Ирина Гостева: "Конечно, - курильщики. И лечение псориаза основывается именно на этом знании. " Екатерина: "У меня обычный псориаз на локтевых сгибах. " Александр Мясников: "Давайте посмотрим, какие участки кожи поражает псориаз." Ирина Гостева: "Есть себорейноподобный псориаз, его очень часто путают доктора, принимая за себорею или перхоть. Чаще всего располагаются в местах сгибов, на локтях, коленях. Чаще всего он появляется летом." Александр Мясников: "Но ведь летом солнце, должен, наоборот, проходить." Ирина Гостева: "К сожалению, нет, есть такая форма псориаза. Также псориаз часто располагается на волосистой части головы. Классическое проявление на руках у курильщиков застарелых раздражений на ладони и подошвах." Александр Мясников: "Помимо кожи иногда псориаз поражает также и суставы. Вообще, бывает летняя форма, и зимняя, которая проявляется в период сырости и холода. Зимнюю хорошо лечить летом, когда много солнечных дней. При летней форме псориаза, наоборот, на солнце он обостряется. Приходится использовать для лечения все за исключением солнца." Екатерина: "Еще у меня была раньше суставная форма псориаза. Локти болели так, что даже чайник не в состоянии была поднять." Александр Мясников: "Теперь давайте поговорим о лечении." Ирина Гостева: "Ирина Гостева: - Неделю назад Екатерина обратилась к нам за помощью в период обострения псориаза на локтевых сгибах. Мы ей прописали курс новейшего препарата, который успешно прошел все клинические испытания и доказал свою состоятельность в борьбе с псориазом - это крем-воск «Здоров». Екатерина, расскажите всем как шел процесс вашего лечения." Екатерина: "Ничего сложного. Втираете крем в пораженные участки кожи, ждете немного, пока впитается. Остались небольшие бляшечки, думаю, пройдут они за 3-4 дня. Я начала пользоваться этим кремом и в первый же день почувствовала, что стало легче. Суставы тоже в полном порядке теперь." Ирина Гостева: "Хочу сказать, что крем «Здоров» - не гормональный препарат. Он постепенно сокращает рост количества делящихся клеток кожи. Она перестает шелушиться, проходит зуд, нормализуется микроциркуляция крови в поверхностных слоях кожи. Все лето сижу дома, так как на солнце с псориазом лучше не показываться. «Здоров» вы можете заказать на официальном сайте поставщика. Fluocinonide is used to treat the itching, redness, dryness, crusting, scaling, inflammation, and discomfort of various skin conditions. This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information. Fluocinonide comes in ointment, cream, solution, and gel in various strengths for use on the skin. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Do not use more or less of it or use it more often than prescribed by your doctor. Do not apply it to other areas of your body or wrap or bandage the treated area unless directed to do so by your doctor. Wash or soak the affected area thoroughly before applying the medicine, unless it irritates your skin. Then apply the ointment, cream, solution, or gel sparingly in a thin film and rub it in gently. To use the solution or gel on your scalp, part your hair, apply a small amount of the medicine on the affected area, and rub it in gently. Protect the area from washing and rubbing until the solution or gel dries. You may wash your hair as usual but not right after applying the medicine. Avoid prolonged use on the face, in the genital and rectal areas, and in skin creases and armpits unless directed by your doctor. If you are using fluocinonide on your face, keep it out of your eyes. If you are using fluocinonide on a child's diaper area, do not use tight-fitting diapers or plastic pants. Do not apply cosmetics or other skin preparations on the treated area without talking with your doctor. However, if it is almost time for the next dose, skip the missed dose and continue your regular dosing schedule. Do not apply a double dose to make up for a missed one. If you experience a serious side effect, you or your doctor may send a report to the Food and Drug Administration's (FDA) Med Watch Adverse Event Reporting program online ( Watch) or by phone (1-800-332-1088). Keep this medication in the container it came in, tightly closed, and out of reach of children. Store it at room temperature and away from excess heat. Throw away any medication that is outdated or no longer needed. Talk to your pharmacist about the proper disposal of your medication. It is important to keep all medication out of sight and reach of children as many containers (such as weekly pill minders and those for eye drops, creams, patches, and inhalers) are not child-resistant and young children can open them easily. Ask your pharmacist any questions you have about refilling your prescription. To protect young children from poisoning, always lock safety caps and immediately place the medication in a safe location – one that is up and away and out of their sight and reach. It is important for you to keep a written list of all of the prescription and nonprescription (over-the-counter) medicines you are taking, as well as any products such as vitamins, minerals, or other dietary supplements. You should bring this list with you each time you visit a doctor or if you are admitted to a hospital. It is also important information to carry with you in case of emergencies.


Fluocinonide ointment псориаз

Fluocinonide ointment псориаз

Неоднократно я писала о том, что уже много лет страдаю таким недугом как псориаз. За 10 лет я посетила огромное количество врачей и опробовала на своей коже разнообразные мази и кремы, но, к сожалению, "воз и ныне там...". Конечно, ранки на моих коленях и локотках периодически становятся меньшими, но еще ни разу они не исчезали полностью. Сегодня я расскажу про Флуоцинонидную мазь для лечения псориаза, экземы и дерматитов, которая тоже меня не излечила, но в использовании очень понравилась, и я однозначно куплю ее еще ни один раз. Наносить локально на проблемные участки 2-3 раза в день (но не более 50г в неделю). При длительном использовании рекомендуется делать перерывы 1-2 недели. В небольшой картонной коробочке спрятана алюминиевая туба. Оформление упаковки соответствует лекарственному препарату - лаконичное и, главное, в зеленом цвете (цвет успокаивающий нервную систему). Туба очень миниатюрная (ее объем 10г), она помещается в ладошку. Довольно нестандартный объем для подобных средств, но очень удобный. Во-первых, туба не занимает много места в тумбочке или в сумочке, а во-вторых, кожа быстро привыкает к таким средствам и через некоторое время эффект ослабевает, приходится менять мазь на другую, а с 10г вряд ли это произойдет. Туба закручивается маленькой пластиковой крышечкой. Открыв ее мы видим кремообразную текстуру белого цвета, которая не имеет запаха. За счет своей легкости мазь очень приятна в использовании. Я наношу ее на пораженные участки и она практически сразу впитывается. Часто похожие мази оставляли жирный след или пленку на моей коже, но эта впитывается полностью и без остатка. После нанесения флуоцинонидной мази сухая кожа мгновенно становится увлажненной, а омертвевшие чешуйки становятся не такими заметными. Если кожные покровы покрыты чешуйками, то никаких неприятных ощущений мазь не вызовет, но если наносить ее на расчесанные ранки, то может появится легкое пощипывание (не катастрофическое). Я использую мазь на протяжении 2 месяцев и первыми результатами довольна. Меня перестал беспокоить дискомфорт на пораженных участках, я перестала их расчесывать до ран. Буду продолжать бороться с псориазом с помощью флуоцинонидной мази и если появятся еще большие сдвиги, то обязательно о них расскажу. Правда, я знаю, что псориаз не вылечивается, а только лишь на время "затихает". Поэтому экспериментировать с мазями можно долго и нудно, но я пожалуй, веберу именно эту. Мазь "Fluocinonide ointment" применяется для лечения аллергического, контактного, себорейного дерматитов, экземы, псориаза, зуда кожи. Если говорить простыми словами, то мазь подходит для лечения аллергий, потницы и различных кожных высыпаний. Нейродермит (заболевание кожи, обусловленное нарушением функции центральной нервной системы), кожный зуд различного происхождения, аллергические заболевания кожи, псориаз, красный плоский лишай. Является эффективным средством для лечения кожного зуда. Линимент применяют у пациентов с островоспалительными экссудативными заболеваниями кожи (мокнущими воспалительными заболеваниями кожи) : себорейной экземой (зудяшим воспалением сальных желез волосистой части головы, лица, груди и спины с выраженными явлениями шелушения кожи), аллергическими дерматитами (воспалении кожи), зуде заднего прохода и половых органов, экссудативной (сопровождающейся выходом из кожи богатой белком жидкости) формой псориаза). Небольшое количество препарата наносят на пораженный участок 2-3 раза в день и слегка втирают в кожу. Для поддержания терапевтического эффекта препарат достаточно нанести на кожу 1-2 раза в день. Продолжительность лечения зависит от характера заболевания и эффективности терапии, составляет обычно 5-10 дней. Курс лечения может быть продлен до 25 дней и более, но не более 50 грамм в неделю.